Microdose Psychedelic Insights

We sat down with Scotch McClure of @MaxwellBiosci to talk about disease prevention, reversing aging, and the future of health. This interview will change how you think about aging: microdose.buzz/news/maxwell-b…

Synthetic immune systems could be the next big breakthrough in biotech. Hear from Scotch McClure, CEO of @MaxwellBiosci, on how they're leading the charge. Watch now: microdose.buzz/news/maxwell-b…

The future of health might lie in our microbiome. Learn how Scotch McClure and @MaxwellBiosci are unlocking the secrets to a longer, healthier life microdose.buzz/news/maxwell-b…

What if we could replace antibiotics and antivirals with one solution? Scotch McClure from @MaxwellBiosci explores this exciting future in our latest interview: microdose.buzz/news/maxwell-b…

Is reversing aging the next big biotech breakthrough? Hear from Scotch McClure, CEO of @MaxwellBiosci, on how their research could transform health and longevity. microdose.buzz/news/maxwell-b…

Imagine a world where aging is reversible. CEO Scotch McClure explains how @MaxwellBiosci is pushing the boundaries of science to make it happen. Watch the full interview here: microdose.buzz/news/maxwell-b…

Scotch McClure from @MaxwellBiosci discusses reversing aging, pathogen-fighting peptides, and their implications for human health in our latest interview: microdose.buzz/news/maxwell-b…

Is aging contagious? Our latest interview with Scotch McClure, CEO of @MaxwellBiosci, explores groundbreaking theories that could reshape how we think about aging and health. Watch now on our website microdose.buzz/news/maxwell-b…

In a powerful interview with @BostonMagazine, actress @elizadushku shares her transformative journey with psychedelic-assisted therapy: bostonmagazine.com/news/2024/09/2…

Mindstate Design Labs AI-Designed Trial Gets FDA Approval Mindstate Design Labs has announced major news, receiving both FDA and European Medicines Agency (EMA) approval to commence human trials of its compound, MSD-001. microdose.buzz/news/mindstate…

Psyence Biomed Announces Acquisition of Psilocybin Drug Developer Clairvoyant Therapeutics Clairvoyant is running a Phase IIb clinical trial evaluating synthetic psilocybin for Alcohol Use Disorder (AUD) microdose.buzz/news/psyence-b…

The FDA panel has rejected the first MDMA treatment for PTSD, citing serious concerns about the quality and reliability of the clinical trials conducted. nbcnews.com/health/health-…

We recently sat down with @neonneurons, CEO of @TerranBio, to discuss the exciting developments in their pipeline, particularly their latest schizophrenia therapeutic, TerXT. Read the full interview here: microdose.buzz/news/interview…

In a new study, researchers from the Centre for Psychedelic Research at @imperialcollege found that on average, people reported improvements across a range of areas of sexual function up to six months after their psychedelic experience, including their enjoyment of sex, sexual arousal, satisfaction with sex, attraction to partner, their own physical appearance, communication, and their sense of connection. imperial.ac.uk/news/251313/ps…

Big News as MAPS PBC Rebrands to Lykos Therapeutics; Closes $100m Series A Funding lykospbc.com/2024/01/05/map…

Atai Life Sciences Invests $50 Million into Beckley Psytech. The investment gives atai a 35.5% ownership share and exposure to Beckley's advanced trials. globenewswire.com/news-release/2…

Microdose takes a look at the top psychedelic stories of 2023. Including: - Australia Legalization - Government Support for Psychedelics - MindMed's Phase 2b LSD Trial - Cybin's Phase 2 Trials for Depression - MAPS New Drug Application With FDA microdose.buzz/news/psychedel…

We take a deeper look at ancient shamanic traditions, exploring how magic mushrooms may be a part of Christmas history microdose.buzz/news/exploring…

Awakn signs global licensing agreement for exclusivity of proprietary S-ketamine oral film formulation $AWKN awaknlifesciences.com/awakn-enters-g…

Terran Biosciences Receives FDA Clearance for MRI Scan Technology Terran gets FDA approval for NM-101, the industry’s first software for the analysis of neuromelanin-sensitive MRI microdose.buzz/news/terran-re…